Efficacy and safety in key patient subgroups of vivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (Checkmate 067) Meeting Abstract
| Authors: | Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassal, J. C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F. S.; Wolchok, J. D. |
| Abstract Title: | Efficacy and safety in key patient subgroups of vivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (Checkmate 067) |
| Meeting Title: | COSA's 42nd Annual Scientific Meeting |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 11 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2015 Nov 17-19 |
| Meeting Location: | Hobart, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2015-11-01 |
| Start Page: | 126 |
| Language: | English |
| ACCESSION: | WOS:000364320800180 |
| PROVIDER: | wos |
| PUBMED: | 26525766 |
| DOI: | 10.1111/ajco.12432_2 |
| Notes: | Meeting Abstract: 204 -- SI -- Source: Wos |
